Fig. 5: BRCA1 expression is related to TMZ resistance in glioma patients.

A Expression of BRCA1 in primary and recurrent gliomas. *p < 0.05 and **p < 0.01 compared with primary glioma by Student’s t test. B Correlation analysis of AKT expression and BRCA1 expression in the indicated recurrent glioma datasets. C, D OS of recurrent glioma patients treated with TMZ based on BRCA1 expression. (Group 1: mRNAseq_325 datasets; Group 2: mRNAseq_693 datasets).